The Central Board of Secondary Education (CBSE) has issued a fourth reminder to all affiliated schools regarding the submission of registration data for Class IX and Class XI for the academic year ...

Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups - ...

Dr. Simon Plyte, Biomunex's CSO, has been invited to present MAIT engagers preclinical data during an oral communication at 2025 SITC Annual meeting With a very attractive safety and efficacy ...

March Biosciences (March Bio), an emerging clinical stage biotechnology company committed to combating challenging cancers and other diseases, today announced that interim clinical data from its ...

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-exp ...

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for ...

– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal ...

Good afternoon, ladies and gentlemen, and welcome to GEN Restaurant Group, Inc. 3Q 2025 Earnings Call. [Operator Instructions] And now I would like to turn the conference over to Mr. Tom Croal, the ...

Third quarter 2025 net revenue was $118.8 million, up slightly compared to $118.6 million in the third quarter of 2024, fueled by the timing of Rejuvenate 2.0 shipments and the continued expansion of ...

RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately-held clinical-stage biopharmaceutical company leading the development of innovative, ...

Anika Therapeutics, Inc. (NASDAQ: ANIK) Q3 2025 Earnings Call Transcript November 5, 2025 Anika Therapeutics, Inc. misses on ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported ...